The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
| Autor: | Sahasrabudhe, V., Terra, S. G., Hickman, A., Saur, D., Shi, H., O'Gorman, M., Zhou, Z., Cutler, D. L. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
renal impairment
Blood Glucose Male ertugliflozin type 2 diabetes mellitus Middle Aged Bridged Bicyclo Compounds Heterocyclic Kidney Special Populations Glucose Diabetes Mellitus Type 2 Glucosides Sodium-Glucose Transporter 2 Humans Hypoglycemic Agents Female Renal Insufficiency sodium‐glucose cotransporter 2 Aged Glomerular Filtration Rate |
| Zdroj: | Journal of Clinical Pharmacology |
| ISSN: | 1552-4604 0091-2700 |
| Popis: | Ertugliflozin is a highly selective and potent inhibitor of the sodium‐glucose cotransporter 2 in development for the treatment of type 2 diabetes mellitus. The glycemic efficacy of sodium‐glucose cotransporter 2 inhibitors such as ertugliflozin depends on glucose filtration through the kidney. This phase 1, open‐label study evaluated the effect of renal impairment on the pharmacokinetics, pharmacodynamics, and tolerability of ertugliflozin (15 mg) in type 2 diabetes mellitus and healthy subjects with normal renal function (estimated glomerular filtration rate not normalized for body surface area ≥90 mL/min) and type 2 diabetes mellitus subjects with mild (60‐89 mL/min), moderate (30‐59 mL/min), or severe ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text